4 results
The objective of this research is to see if this way of treating a patient ensures a quicker diagnosis, which results in lessabdominal pain for the patient.
This study aims to test the hypothesis that zandelisib in combination with rituximab has better clinical activity and risk/benefit profile compared to standard 2nd line immunochemotherapy (R-CHOP/R-B) in subjects with relapsed FL or MZL. Primary…
Primary ObjectiveThe primary objective of this study is to evaluate whether the addition of ibrutinib to bendamustine and rituximab will result in prolongation of PFS in subjects with newly diagnosed MCL who are 65 years of age or older.Secondary…
To test whether immediate complete revascularization is non-inferior to staged (but within six weeks after index procedure) complete revascularization in ACS patients with multivessel disease